Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Adam L. Maddox has a total of 41 co-authors. Here are the top co-authors by number of shared publications:

  • Tijana Jovanovic-Talisman

    Department of Cancer Biology and Molecular Medicine, Beckman Research Institute, City of Hope National Medical Center, United States

    3 shared publications
  • Andras Saftics

    Department of Cancer Biology and Molecular Medicine, Beckman Research Institute, City of Hope Comprehensive Cancer Center, Duarte, California 91010, United States

    2 shared publications
  • Victoria L. Seewaldt

    City of Hope Comprehensive Cancer Center, 1500 East Duarte Road, Duarte, CA 91010, USA

    2 shared publications
  • Ajay Goel

    Center for Gastrointestinal Research, Center for Translational Genomics and Oncology, Baylor Scott & White Research Institute and Charles A. Sammons Cancer Center, Baylor University Medical Center, Dallas, TX, USA

    1 shared publication
  • Andrew To

    Department of Cellular and Molecular Medicine, University of California at San Diego, La Jolla, CA 92093-0651

    1 shared publication
  • Anthony Leyme

    Department of Biochemistry, Boston University School of Medicine, Boston, MA 02118

    1 shared publication

Latest Publications

  • Open Access

    Molecular Atlas of HER2+ Breast Cancer Cells Treated with Endogenous Ligands: Temporal Insights into Mechanisms of Trastuzumab Resistance

    by Kavitha Mukund, Jackelyn A. Alva-Ornelas, Adam L. Maddox, Divya Murali, Darya Veraksa, Andras Saftics, Jerneja Tomsic, David Frankhouser, Meagan Razo, Tijana Jovanovic-Talisman, et al.

    Trastuzumab therapy in HER2+ breast cancer patients has mixed success owing to acquired resistance to therapy. A detailed understanding of downstream molecular cascades resulting from trastuzumab resistance is yet to emerge. In this study, we investigate the cellular mechanisms underlying acquired resistance using trastuzumab-sensitive and -resistant cancer cells (BT474 and BT474R) treated with endogenous ligands EGF and HRG across time. We probe early receptor organization through microscopy and signaling events through multiomics measurements and assess the bioenergetic state through mitochondrial measurements. Integrative analyses of our measurements reveal significant alterations in EGF-treated BT474 HER2 membrane dynamics and robust downstream activation of PI3K/AKT/mTORC1 signaling. EGF-treated BT474R shows a sustained interferon-independent activation of the IRF1/STAT1 cascade, potentially contributing to trastuzumab resistance. Both cell lines exhibit temporally divergent metabolic demands and HIF1A-mediated stress responses. BT474R demonstrates inherently increased mitochondrial activity. HRG treatment in BT474R leads to a pronounced reduction in AR expression, affecting downstream lipid metabolism with implications for treatment response. Our results provide novel insights into mechanistic changes underlying ligand treatment in BT474 and BT474R and emphasize the pivotal role of endogenous ligands. These results can serve as a framework for furthering the understanding of trastuzumab resistance, with therapeutic implications for women with acquired resistance.


  • Open Access

    Molecular Assessment of HER2 to Identify Signatures Associated with Therapy Response in HER2-Positive Breast Cancer

    by Adam L. Maddox, Matthew S. Brehove, Kiarash R. Eliato, Andras Saftics, Eugenia Romano, Michael F. Press, Joanne Mortimer, Veronica Jones, Daniel Schmolze, Victoria L. Seewaldt, et al.

    Trastuzumab, the prototype HER2-directed therapy, has markedly improved survival for women with HER2-positive breast cancers. However, only 40–60% of women with HER2-positive breast cancers achieve a complete pathological response to chemotherapy combined with HER2-directed therapy. The current diagnostic assays have poor positive-predictive accuracy in identifying therapy-responsive breast cancers. Here, we deployed quantitative single molecule localization microscopy to assess the molecular features of HER2 in a therapy-responsive setting. Using fluorescently labeled trastuzumab as a probe, we first compared the molecular features of HER2 in trastuzumab-sensitive (BT-474 and SK-BR-3) and trastuzumab-resistant (BT-474R and JIMT-1) cultured cell lines. Trastuzumab-sensitive cells had significantly higher detected HER2 densities and clustering. We then evaluated HER2 in pre-treatment core biopsies from women with breast cancer undergoing neoadjuvant therapy. A complete pathological response was associated with a high detected HER2 density and significant HER2 clustering. These results established the nano-organization of HER2 as a potential signature of therapy-responsive disease.


  • Open Access

    Single molecule characterization of individual extracellular vesicles from pancreatic cancer

    by Kathleen M. Lennon, Devin L. Wakefield, Adam L. Maddox, Matthew S. Brehove, Ari N. Willner, Krystine Garcia‐Mansfield, Bessie Meechoovet, Rebecca Reiman, Elizabeth Hutchins, Marcia M. Miller, et al.

    Biofluid‐accessible extracellular vesicles (EVs) may represent a new means to improve the sensitivity and specificity of detecting disease. However, current methods to isolate EVs encounter challenges when they are used to select specific populations. Moreover, it has been difficult to comprehensively characterize heterogeneous EV populations at the single vesicle level. Here, we robustly assessed heterogeneous EV populations from cultured cell lines via nanoparticle tracking analysis, proteomics, transcriptomics, transmission electron microscopy, and quantitative single molecule localization microscopy (qSMLM). Using qSMLM, we quantified the size and biomarker content of individual EVs. We applied qSMLM to patient plasma samples and identified a pancreatic cancer‐enriched EV population. Our goal is to advance single molecule characterization of EVs for early disease detection.Abbreviations: EV: Extracellular Vesicle; qSMLM: quantitative Single Molecule Localization Microscopy; PDAC: Pancreatic Ductal Adenocarcinoma; EGFR: epidermal growth factor receptor 1; CA19‐9: carbohydrate antigen 19‐9; SEC: size exclusion chromatography; WGA: wheat germ agglutinin; AF647: Alexa Fluor 647; Ab: antibody; HPDEC: Healthy Pancreatic Ductal Epithelial Cell; TEM: Transmission Electron Microscopy.


  • Cyclin-dependent kinase 5 activates guanine nucleotide exchange factor GIV/Girdin to orchestrate migration–proliferation dichotomy

    by Deepali Bhandari, Inmaculada Lopez-Sanchez, Andrew To, I-Chung Lo, Nicolas Aznar, Anthony Leyme, Vijay Gupta, Ingrid Niesman, Adam L. Maddox, Mikel Garcia-Marcos, et al.

    Significance: The guanine nucleotide exchange factor (GEF) GIV/Girdin has previously been shown to trigger noncanonical activation of trimeric G proteins in response to multiple chemical stimuli at the plasma membrane and at various locations within cells. In this work we identified a single phosphoevent and pinpointed cyclin-dependent kinase 5 (CDK5) as the responsible kinase that activates GIV's GEF function and initiates noncanonical G protein signaling via GIV. These studies provide evidence that CDK5 is essential for maximal activation of GIV-GEF in cells and insights into a hitherto unrecognized crosstalk between CDK5 and G proteins via GIV. Such crosstalk may shape migration–proliferation dichotomy during several physiological and pathological scenarios such as wound healing and cancer metastasis.